ADEF
SYRE icon

ABS Direct Equity Fund’s Spyre Therapeutics SYRE Stock Holding History

ABS Direct Equity Fund’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$186K Sell
89
-2,711
-97% -$198K 0.12% 97
2026
Q1 		$194K Buy
+2,800
New +$106K 0.15% 82

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

ABS Direct Equity Fund's SYRE Position: Q2 2026 in Review

ABS Direct Equity Fund reduced its Spyre Therapeutics (SYRE) stake by 97% in Q2 2026, selling an estimated $198K and leaving 89 shares worth $186K. The position accounts for 0.12% of the portfolio, ranked #97.

ABS Direct Equity Fund first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. The position peaked at $194K in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • ABS Direct Equity Fund held 89 shares of Spyre Therapeutics worth $186K as of Q2 2026.
  • ABS Direct Equity Fund sold 2,711 Spyre Therapeutics shares in Q2 2026, an estimated $198K.
  • Spyre Therapeutics made up 0.12% of ABS Direct Equity Fund's portfolio in Q2 2026, its #97 holding.
  • ABS Direct Equity Fund first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • ABS Direct Equity Fund's Spyre Therapeutics position peaked at $194K in Q1 2026.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on ABS Direct Equity Fund's 13F filing for Q2 2026, filed 13 Aug 2026.